
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. is well-positioned for a positive financial outlook due to its innovative approach in developing therapies that utilize the PROTAC platform, which demonstrated notable enhancements in safety profiles and potency in comparative assays. The advantages shown by ARV-806, particularly its superior efficacy in reducing KRAS G12D protein and enhancing immune response compared to existing inhibitors, indicate significant potential for its application in cancer treatment. With upcoming milestones, including the anticipated approval of vepdeg by June 2025, the company's strategic focus on improving treatment outcomes for challenging diseases reinforces confidence in its future growth prospects.
Bears say
Arvinas Inc. faces a negative outlook primarily due to significant revenue forecasts being downgraded, with peak vepdeg revenue expectations slashed to $296.9 million from a prior estimate of $641.2 million, indicating challenges in market penetration and partnered economics. Furthermore, the company’s inability to access capital could hinder critical business functions, potentially delaying profitability and sustainable cash flow generation. Additionally, a sequential decline in expenditures on key product candidates reflects a reduced commitment to development spending, which may impede the company's ability to defend its market position and hinder growth prospects.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares